Decentralized clinical trials (DCTs) were a boon during the pandemic. Pharmaceutical enterprises capitalized on the opportunity to conduct remote and virtual trials during a time when isolation was critical. However, in 2023, pharmaceutical enterprises are turning their focus to address new challenges such as scale, data security, and site engagement.

In this webinar, our experts presented insights on the trends pharmaceutical enterprises should expect this year, along with data from our 2023 DCT Platforms PEAK Matrix^® assessment to shed light on both the demand and supply side of this market.

Our speakers discussed:

• How is the DCT technology market evolving and what does adoption look like across therapy areas and geographies?
• What sourcing criteria should pharmaceutical enterprises consider for evaluating their DCT needs?
• What are the supply landscape characteristics and their value propositions?